96. クローン病 Crohn disease Clinical trials / Disease details

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

76 trials found

diseases per page:

Showing 1 to 10 of 76 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05088369 (ClinicalTrials.gov)	November 11, 2021	12/10/2021	Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201	A First-in-human, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerabili ...	Ulcerative Colitis;Crohn's Disease	Drug: HM201;Drug: Placebo	Syneos Health	Himuka AM Pharma Corp.	Completed	18 Years	55 Years	All	53	Phase 1	Australia
2	NCT04643483 (ClinicalTrials.gov)	June 2021	19/11/2020	A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolesc ...	A Phase 3, Randomized, Double-Blind, Multicenter Study Including an Active Reference Arm to Evaluate ...	Crohn's Disease	Drug: Certolizumab pegol;Drug: Adalimumab;Drug: Placebo	UCB Biopharma SRL	NULL	Withdrawn	6 Years	17 Years	All	0	Phase 3	NULL
3	NCT04163016 (ClinicalTrials.gov)	June 19, 2020	24/10/2019	A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol ...	A Postmarketing, Multicenter, Longitudinal, Prospective, Pharmacokinetic, Phase 1B Study in Pregnant ...	Rheumatoid Arthritis;Psoriatic Arthritis;Crohn's Disease;Axial Spondyloarthritis;Plaque Psoriasis	Drug: Pharmacokinetics of certolizumab pegol	UCB Biopharma S.P.R.L.	NULL	Active, not recruiting	18 Years	N/A	Female	22	Phase 1	United States;France;Germany;Spain;Switzerland;Canada;Netherlands
4	NCT03559660 (ClinicalTrials.gov)	March 2, 2020	5/6/2018	CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)	Compassionate Use Program Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD) ...	Crohn's Disease	Drug: Certolizumab Pegol	UCB Biopharma S.P.R.L.	NULL	Available	18 Years	N/A	All			NULL
5	NCT03357471 (ClinicalTrials.gov)	November 3, 2017	23/11/2017	Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol ...	A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Inje ...	Moderate and Severe Active Rheumatoid Arthritis;Active Psoriatic Arthritis;Active Ankylosing Spondyl ...	Drug: e-Device	UCB Biopharma S.P.R.L.	NULL	Completed	18 Years	N/A	All	70	Phase 3	United States
6	NCT02597829 (ClinicalTrials.gov)	November 2015	27/10/2015	Does Clinical Response Correlate With Serum Certolizumab Levels?	Does Clinical Response Correlate With Serum Certolizumab Levels? A Prospective Open Label Trial of A ...	Crohn's Disease	Drug: Certolizumab Pegol	Shafran Gastroenterology Center	UCB Pharma;UCB Pharma	Not yet recruiting	18 Years	70 Years	Both	20	Phase 4	United States
7	NCT02154425 (ClinicalTrials.gov)	September 2014	30/5/2014	A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of ...	A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast ...	Axial Spondyloarthritis (AxSpA);Non-radiographic Evidence-AxSpA;Ankylosing Spondylitis;Crohn's Disea ...	Procedure: Breast milk sampling;Biological: Certolizumab Pegol	UCB BIOSCIENCES, Inc.	PPD;Parexel	Completed	18 Years	N/A	Female	17	Phase 1	United States;Netherlands;Switzerland;France
8	NCT02073526 (ClinicalTrials.gov)	May 2013	9/1/2014	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis	Drug: Infliximab , adalimumab, certolizumab pegol	Oslo University Hospital	NULL	Completed	18 Years	N/A	Both	1230	N/A	Norway
9	NCT01817972 (ClinicalTrials.gov)	March 2013	19/3/2013	Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease	A Phase III, Randomized, Double-blind Trial in the Comparison of Cimzia Versus Cimzia Plus Azathiopr ...	Crohn's Disease	Biological: Certolizumab pegol;Drug: Azathioprine	Gastroenterology Research of America	UCB Pharma	Not yet recruiting	18 Years	70 Years	Both	65	Phase 3	United States
10	EUCTR2009-017998-37-BE (EUCTR)	08/06/2012	11/04/2012	Scintigraphic detection of tumor necrosis factor with radioactive labeled TNFa-blocker in patients w ...	Scintigraphic detection of tumor necrosis factor with radioactive labeled TNFa-blocker in patients w ...	Patients with an active spondyloarthropathy and with an active rheumatoid arthritis; who were diagno ...	Trade Name: Cimzia 200 mg solution for injection Product Name: Certolizumab pegol INN or Proposed INN: ...	Ghent University Hospital	NULL	Not Recruiting			Female: yes Male: yes	36	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Belgium

First Previous1 2 3 4 5…8Next Last